Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: Baskent University experience.

e16001 Background: Majority of patients with head and neck cancer present with locally advanced disease. Most of the patients are treated with concurrent chemoradiotherapy. However, the toxicities are substantial and can be associated with severe local and systemic toxicities. Alternate schedules of cisplatin have been tried to overcome these toxicities. No formal comparison, however, has been reported between alternate schedules and reference regimen in literature. The primary aim is to report a retrospective study comparing alternate schedule of cisplatin with standard three weekly bolus cisplatin in terms of effectiveness and related toxicities. Methods: Patients with head and neck cancers who were treated with concurrent chemoradiotherapy in our center between periods of 2007-2009 were retrospectively analyzed. Basic demographics and clinical characteristics’ of the patients were collected. Parameters such as overall survival rate, locoregional or systemic relapse rates, and time to local/systemic rel...